This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
MDEA: Difference between revisions
>Unity m Grammatics |
>Niamh Summary - shulgin's initial tests, first published synthesis (the 1967 compound tested was methylenedioxyethanolamine not MDEA) |
||
| Line 5: | Line 5: | ||
'''3,4-Methylenedioxy-N-ethylamphetamine''' (also known as, '''Methylenedioxyethylamphetamine''', '''MDEA''', '''MDE''', and colloquially as '''Eve''') is an obscure, synthetic [[Psychoactive class::entactogen]] of the [[Chemical class::amphetamines|substituted amphetamine]] class that produces modified [[MDMA|MDMA-like]] entactogenic effects when [[routes of administration|administered]]. It is a closely related structural analog of [[MDMA]] and [[MDA]]<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref> that acts via the same pharmacological mechanism as a [[serotonin]], [[norepinephrine]], and [[dopamine]] [[releasing agent]] and [[reuptake inhibitor]].<ref name="MDEApharm">Freudenmann RW, Spitzer M (2004). "The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA)". CNS Drug Reviews. 10 (2): 89–116. https://doi.org10.1111/j.1527-3458.2004.tb00007.x. PMID 15179441.</ref> | '''3,4-Methylenedioxy-N-ethylamphetamine''' (also known as, '''Methylenedioxyethylamphetamine''', '''MDEA''', '''MDE''', and colloquially as '''Eve''') is an obscure, synthetic [[Psychoactive class::entactogen]] of the [[Chemical class::amphetamines|substituted amphetamine]] class that produces modified [[MDMA|MDMA-like]] entactogenic effects when [[routes of administration|administered]]. It is a closely related structural analog of [[MDMA]] and [[MDA]]<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref> that acts via the same pharmacological mechanism as a [[serotonin]], [[norepinephrine]], and [[dopamine]] [[releasing agent]] and [[reuptake inhibitor]].<ref name="MDEApharm">Freudenmann RW, Spitzer M (2004). "The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA)". CNS Drug Reviews. 10 (2): 89–116. https://doi.org10.1111/j.1527-3458.2004.tb00007.x. PMID 15179441.</ref> | ||
The first recorded human use of MDEA was in 1976 by [[Alexander Shulgin]], who noted its similarity to [[MDMA]] in both effects and potency, though faster to act and shorter in duration.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #2". Lafayette, CA. (1976-1980). p206 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook2_searchable.pdf</ref>. The synthesis and pharmacological evaluation of MDEA and a series of related compounds were published in 1980.<ref>Braun U, Shulgin AT, Braun G. "Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine)." J Pharm Sci. 1980 Feb;69(2):192-5. | https://www.ncbi.nlm.nih.gov/pubmed/6102141</ref>. MDEA is included in Shulgin's 1991 book "[[PiHKAL]]" ("[[Phenethylamine]]s I Have Known and Loved").<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>. | |||
In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance two years later.<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref> Since then, MDEA has rarely been sold on its own and has largely been used as an occasional additive or substitute ingredient in pills of "Ecstasy".<ref name="MDEApharm" /> | In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance two years later.<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref> Since then, MDEA has rarely been sold on its own and has largely been used as an occasional additive or substitute ingredient in pills of "Ecstasy".<ref name="MDEApharm" /> | ||